Zilico Ltd, which is part of the Deepbridge Life Sciences EIS fund, has recently received a Business Innovation Award for using bioelectrical technology for the development of more accurate medical device diagnostics, which provide results in real time leading to better patient outcomes. 

The award recognises Zilico's excellence in innovation and delivery of significant societal impact through the application of physics, which won Zilico the prestigious Institute of Physics Business Innovation Award 2022. 

The Institute of Physics (IOP) is the professional body and learned society for physics, and the leading body for practising physicists, in the UK and Ireland. With a rich history of supporting business innovation and growth, it is committed to working with ‘physics-based’ businesses, and companies that apply and employ physics and physicists. The IOP’s prestigious Business Awards are unique in the UK and Ireland in recognising the significant contribution that physicists and physics make in industry. There are three categories of awards – Business Innovation, Business Start-Up and the Lee Lucas Award (for the medical and healthcare sector) – so businesses at any stage of their development are eligible; from start-ups to multi-national corporations. 

Sameer Kothari, Chief Executive Director of    Zilico  Ltd,  commented:    

“We at Zilico are honoured to win the IOP Business Innovation Award for our innovative diagnostic for cervical cancer. ZedScan has already benefited thousands of patients across the NHS and international hospitals. We are driven to improve cancer diagnostics, especially within women’s health, an area that has been underserved. This recognition by the IOP makes us at Zilico hugely proud and reinvigorates our drive and passion for better outcomes for patients within cancer pathways.” 

Zilico Ltd has developed an innovative cancer diagnostic device technology that employs Electrical Impedance Spectroscopy (‘EIS’) within a device that seeks to improve and extend current cancer screening programmes, by providing accurate and objective results in real-time. The initial focus of the Company is to address the detection of cervical cancer and oral cancer, and the Company plans to apply the same approach to oesophageal, anal, vaginal and vulva cancers.  The Company’s device, called  ZedScan, examines the electrical resistance properties of human tissues, through the measurement and interpretation of electrical resistance of that tissue and then provides an objective method to differentiate between normal, pre-cancerous, and cancerous cells. 

Cervical cancer affects 3,197 women each year in the UK with a survival percentage of 51%, according to Cancer Research UK.  

Click here to find out more. (By following this link, you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).